RCT: In patients with advanced esophageal squamous-cell carcinoma, both nivolumab plus chemotherapy and nivolumab plus ipilimumab resulted in longer overall survival than chemotherapy alone.

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary (2021 ASCO Annual Meeting): Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Advanced Esophageal Cancer – The ASCO Post

Commentary on Twitter

First-line treatment of advanced esophageal squamous-cell carcinoma with either nivolumab plus chemo or nivolumab plus ipilimumab resulted in a significant overall survival benefit and durable responses as compared with chemo alone. https://t.co/a000bDsh1N pic.twitter.com/NuY2eX58gp

— NEJM (@NEJM) February 2, 2022